PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsReviewsEvent Review: Curing the Incurable — The promises of genome editing

BioNews

Event Review: Curing the Incurable — The promises of genome editing

Published 12 March 2021 posted in Reviews and appears in BioNews 1087

Author

Dr Yvonne Collins

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Scientific American in partnership with Cellectis, hosted a virtual event to explore genome editing and its use in the clinic. Three pioneers of the field were invited to discuss the early days of genome editing, new technologies and future challenges...

Scientific American in partnership with Cellectis, hosted a virtual event to explore genome editing and its use in the clinic. Three pioneers of the field were invited to discuss the early days of genome editing, new technologies and future challenges.

I had high expectations going into this event, so I was really glad that it didn't disappoint. The discussions were lively, the panelists were enthusiastic and there were plenty of thought-provoking moments. Overall, it turned out to be a welcome escape from lockdown fatigue.

After a brief introduction, Dr Dan Ferber, senior editor at Nature Research Custom Media, opened the discussion by asking: what were the key scientific breakthroughs and turning points? When did we realise genome editing might make a difference in the clinic?

George Church, professor of genetics at Harvard Medical School and professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology (MIT), and considered to be the father of genome engineering, gave a brief history of the technology. It was interesting to hear him reflect on his work as a PhD student in the 1970s and outline the challenges faced by researchers then and now.

Dr André Choulika, CEO of Cellectis, followed this up with an animated account of what it was like to be a protein engineer 20 years ago. He described the struggles they faced as they tried to alter proteins, known as nucleases, to recognise and edit naturally occurring genes. He spoke passionately about his research and the discovery of TALENs that eventually brought him to the conclusion that 'nuclease-based genome editing could become a therapeutic approach.'

Unsurprisingly the conversation then turned to CRISPR/Cas9. Dr Choulika recalled how he first found out about the technology in 2012 and how it revolutionised the field. He said it 'totally invaded earth,' it rapidly went 'viral.' The technology was so accessible that anyone could become a gene editor, you didn't need to be an expert in protein engineering, and that's why it won the Noble prize.

The audience were then given an insight into how genome editing could be used to treat blood and immune diseases. One of the pioneers of cell-based CRISPR therapies, Matthew Porteus, professor and physician at Stanford University, spoke profoundly about the inadequacy of current treatments and the promise of stem cell technology and genome editing. He also highlighted some of the safety concerns and importance of considering treatment in the context of what's happening naturally – how do we deal with the fact that our genomes are changing every time our cells divide? It seems obvious, but it's not something I'd previously given much thought.

Dr Choulika followed up with an overview of CAR-T therapies developed by Cellectis. In simple terms, the technology involves engineering T-cells to find and destroy cancer cells. This was the only moment when the discussion got a bit too technical and the sound quality made it difficult to follow.

Fortunately, Dr Choulika held the audience's attention by giving a real-world account of how the therapy saved a young girl from life-threatening leukaemia. He described the success simply as 'the first example of gene edited T-cells in a patient.' Professor Porteus was more enthusiastic, adding, 'the fact she's alive five years later is remarkable.'

Considering the glowing review, I was surprised to hear that only 60-70 patients are currently receiving this treatment. Unfortunately, it wasn't discussed further, but I guess it's because the technology – which uses TALENs – is known to be less flexible and more technically demanding.

The final topic for discussion was ethics. Professor Church raised a valid point, saying that right now there's more demand for somatic genome editing and no compelling reason to use germline editing. He also rightly pointed out that trials would take too long, especially for late onset diseases. Professor Porteus concluded that the availability of somatic genome editing, alongside IVF and preimplantation screening, would greatly reduce the need for germline genome editing.

Professor Porteus closed the discussion poignantly, saying that germline editing is an intentional change that has the potential to affect the whole of humanity. He said the decision to 'cross that line' is not one that can be made by scientist alone, it needs buy-in from all of humanity.

The event ended with a brief Q&A. The topics covered included:  what are the likely targets and treatment in the next five years? What technology can we expect beyond CRISPR and how might genome editing be used to treat HIV and childhood diseases?

Despite a few technical issues, I thought the format worked well. I particularly liked the fact that very few slides were used so it felt more like a conversation. I also thought the speakers did a great job of keeping the energy up throughout, which is not always easy with a virtual event.

Sources and References

  • 24/02/2021
    Scientific American Custom Media
    Curing the incurable: the promises of genome editing

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
8 April 2022 • 2 minutes read

Genes affecting HIV infection identified using CRISPR genome editing

by Devika Sooklall

Genome editing of blood could provide new treatments for HIV according to a new study...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
24 September 2021 • 2 minutes read

First genome editing treatment for HIV enters clinical trials

by Abbie Harper

A CRISPR-based therapy developed as a potential cure for HIV has been approved for human clinical trials by the US Food and Drug Administration...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Reviews
4 June 2021 • 5 minutes read

Event Review: Shining a Light on Genetic Disorders – Genetic eye disorders

by Joseph Hamilton

The Institute of Genetics and Cancer at the University of Edinburgh virtually hosted their seventh genetic eye disease conference in June 2021, connecting geneticists, clinicians and researchers from the Medical Reseach Council Human Genetics Unit...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
7 May 2021 • 2 minutes read

Retron genome editing approach is faster and easier than CRISPR

by Rachel Siden

A new genome editing approach may be faster and simpler than CRISPR...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
30 April 2021 • 2 minutes read

CRISPR genome editing corrects a Duchenne muscular dystrophy deletion mutation in mice

by Christina Burke

Two genome editing approaches can correct a variety of mutations associated with Duchenne muscular dystrophy, researchers have shown...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
28 January 2021 • 2 minutes read

TALENs outperforms CRISPR/Cas9 in editing compact DNA

by Dr Molly Godfrey

Researchers comparing different methods of genome editing have found that in some contexts, TALENs work more efficiently than CRISPR/Cas9...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
12 October 2020 • 5 minutes read

A pathway to nowhere? A critique of the National Academy of Sciences report on genome editing

by Dr Chris Gyngell

The transformative impact of CRISPR/Cas9 genome editing was recognised last week, with the Nobel Prize being awarded to its founders Jennifer Doudna and Emmanuelle Charpentier...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Book Review: Freezing Fertility — Oocyte cryopreservation and the gender politics of ageing

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
1 August 2022 • 3 minutes read

Podcast Review: Stories of Our Times – IVF, fraud and 'unwanted' children

25 July 2022 • 4 minutes read

TV Review: DNA Family Secrets – series two, episode six

18 July 2022 • 4 minutes read

TV Review: Spotlight – The babymaker uncovered

4 July 2022 • 3 minutes read

Podcast Review: Biohacked Family Secrets – The birth of the sperm bank

20 June 2022 • 5 minutes read

Documentary Review: Our Father

15 August 2022 • 3 minutes read

Radio Review: The Life Scientific – Shankar Balasubramanian on decoding DNA

8 August 2022 • 4 minutes read

Podcast Review: Babbage – Editing the code of life

1 August 2022 • 3 minutes read

Podcast Review: Stories of Our Times – IVF, fraud and 'unwanted' children

25 July 2022 • 4 minutes read

TV Review: DNA Family Secrets – series two, episode six

18 July 2022 • 4 minutes read

TV Review: Spotlight – The babymaker uncovered

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856